PSG Report Finds Cost Management Remains Payers' Top Goal as Coverage Strategy for New Drugs and Indications Emerges as Biggest Specialty Drug Management Challenge [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
DALLAS, April 27, 2026 BUSINESS WIRE Pharmaceutical Strategies Group ("PSG"), an EPIC company, today released its 2026 Trends in Specialty Drug Benefits Report, providing new insights into how payers are navigating rising specialty drug costs, increasing treatment complexity, and the growing challenge of balancing affordability with access. The report, now in its 13 th year, was co-sponsored by Genentech. PSG's research found that payers are placing more attention on specialty drugs covered under the medical benefit, showing greater willingness to accept fewer rebates in exchange for stronger utilization management controls, and re-evaluating whether current PBM management models are aligned with their best interests. "Payers continue to prioritize managing specialty drug trend and total cost of care," said Morgan Lee, Vice President of Research and Marketing at PSG. "At the same time, they are working to develop effective coverage strategies for new drugs and expanded indication
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Roche (RHHBY) was upgraded by Morgan Stanley from "underweight" to "equal weight". They now have a $46.00 price target on the stock.MarketBeat
- Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME' Campaign [Yahoo! Finance]Yahoo! Finance
- Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ CampaignBusiness Wire
- Roche Holding AG (RHHBY) Q1 2026 Sales/Trading Call Transcript [Seeking Alpha]Seeking Alpha
- LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor [Yahoo! Finance]Yahoo! Finance